http://www.mmm-online.com/earnings/topic/15419/ Articles tagged with Earnings from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor. http://www.mmm-online.com/business-briefs-pfizer-bms-cms-sanofi/article/293671/ Thu, 16 May 2013 16:50:50 GMT Pfizer cuts 136 workers loose in Ireland, BMS is investing in heart failure treatments, CMS has an official new leader, and Sanofi's iBGStar may have a competitor. MMM The CEO's unexpected departure is part of the health information brand's latest changes. On the table: possible acquisitions. In progress: a new federal contract and new website content. Ignored: if the company wants to be bought. http://www.mmm-online.com/webmd-on-the-hunt-for-new-business/article/292516/ Wed, 08 May 2013 16:41:36 GMT The CEO's unexpected departure is part of the health information brand's latest changes. On the table: possible acquisitions. In progress: a new federal contract and new website content. Ignored: if the company wants to be bought. MMM The portal announced Tuesday that Cavan Redmond, who took the top job there just weeks shy of one year back, is no longer with the company. http://www.mmm-online.com/webmd-ceo-out-after-a-year/article/292374/ Tue, 07 May 2013 21:26:29 GMT The portal announced Tuesday that Cavan Redmond, who took the top job there just weeks shy of one year back, is no longer with the company. MMM Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling. http://www.mmm-online.com/business-briefs-sanofi-allergan-otsuka-genmab-nih-novartis-doj/article/291724/ Thu, 02 May 2013 16:33:13 GMT Lantus cushions Sanofi's quarterly sales; Allergan holds back on Eylea competitor; FDA limits use of Otsuka drug; Genmab lands Breakthrough label; NIH finds a link among cancers; and Novartis offers lunch with a side of medical information; DOJ appeals Plan-B Ruling. MMM Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise. http://www.mmm-online.com/merck-throws-more-staff-behind-januvia-overall-sales-slid-for-quarter/article/291560/ Wed, 01 May 2013 17:33:58 GMT Sales fell more sharply during the quarter than execs expected, and Merck said it has put more Januvia-only reps behind its diabetes franchise. MMM Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe. http://www.mmm-online.com/breakup-xeljanz-plans-dominate-pfizer-earnings-call/article/291220/ Tue, 30 Apr 2013 16:32:13 GMT Sales slipped 9% during the quarter, compared to the same period last year, but analysts zeroed in on if and when the company will split and how arthritis pill Xeljanz will tackle Europe. MMM Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much. http://www.mmm-online.com/abbvie-reports-first-ever-quarter-downplays-pfizer-impact/article/290774/ Fri, 26 Apr 2013 17:11:16 GMT Humira led in sales and the company told analysts Pfizer's Xeljanz setback in Europe won't alter its RA future all that much. MMM An agency bellwether, PHCG is hoping to return to growth after a tame 2012, its CEO said this week. http://www.mmm-online.com/after-rough-12-phcg-looks-to-inject-more-life-into-business/article/290582/ Thu, 25 Apr 2013 18:50:41 GMT An agency bellwether, PHCG is hoping to return to growth after a tame 2012, its CEO said this week. MMM Execs unveiled 10% sales growth and told investors the safety news does not implicate their just-approved MS pill. http://www.mmm-online.com/biogen-reports-sales-jump-backs-tolerability-of-new-ms-pill/article/290570/ Thu, 25 Apr 2013 18:07:07 GMT Execs unveiled 10% sales growth and told investors the safety news does not implicate their just-approved MS pill. MMM Brass-plated brands Plavix and Seroquel continue to lose luster on the two drug makers' balance sheets. http://www.mmm-online.com/patent-losses-stalk-bms-az-quarterly-results/article/290562/ Thu, 25 Apr 2013 17:34:05 GMT Brass-plated brands Plavix and Seroquel continue to lose luster on the two drug makers' balance sheets. MMM